Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.56 |
| ▸ | RAB9A | P51151 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | GLA | P06280 | 1/20 | 0.56 |
| ▸ | CASP3 | P42574 | 1/20 | 0.56 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.56 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.56 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.46 |
| ▸ | DTYMK | P23919 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | HPD | P32754 | 3/20 | 0.44 |
| ▸ | RXRB | P28702 | 1/20 | 0.43 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11643661 | 0.87 | DTYMK (0.57) | NPC1MAPK1RAB9AALDH1A1HTT | |
| SCHEMBL8492671 | 0.85 | NPC1 (0.51) | NPC1MAPK1RAB9AALDH1A1HTT | |
| SCHEMBL442397 | 0.83 | HPD (0.60) | ALDH1A1HTTTDP1TSHRLMNA | |
| SCHEMBL22493011 | 0.83 | ALDH1A1 (0.54) | NPC1MAPK1RAB9AALDH1A1HTT | |
| Ammonia Solution, Strong SCHEMBL28953061 | 0.82 | HPD (0.59) | ALDH1A1HTTTDP1TSHRLMNA | |
| Hydrochloric Acid SCHEMBL11776053 | 0.82 | HPD (0.59) | ALDH1A1HTTTDP1TSHRLMNA | |
| SCHEMBL29115638 | 0.81 | ALDH1A1 (0.48) | NPC1MAPK1RAB9AALDH1A1HTT | |
| SCHEMBL8492000 | 0.81 | MAPT (0.49) | ALDH1A1HTTTDP1TSHRDTYMK | |
| SCHEMBL8942455 | 0.81 | MAPT (0.49) | ALDH1A1HTTTDP1TSHRDTYMK | |
| SCHEMBL8493040 | 0.80 | ALDH1A1 (0.50) | NPC1MAPK1RAB9AALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3619205-B1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK NO 5 LTD (GB) | 2022-04-06 | — | — | EP | disclosed |
| US-10954252-B1 | Inhibitors of human immunodeficiency virus replication | VIIV Healthcare UK (No.5) Limited (GB) | 2021-03-23 | — | — | US | disclosed |
| US-20210032207-A1 | QUINOLONE COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-02-04 | — | — | US | disclosed |
| EP-3619205-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2020-03-11 | — | — | EP | disclosed |
| US-20200055823-A1 | QUINOLONE COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2020-02-20 | — | — | US | disclosed |
| WO-2019057969-A1 | DUAL AGONISTS OF FXR AND PPARδ AND THEIR USES | Johann Wolfgang Goethe-Universität (DE) | 2019-03-28 | — | — | WO | disclosed |
| US-20190077762-A1 | QUINOLONE COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2019-03-14 | — | — | US | disclosed |
| WO-2018203235-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2018-11-08 | — | — | WO | disclosed |
| US-20170362180-A1 | QUINOLONE COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2017-12-21 | — | — | US | disclosed |
| US-9691555-B2 | Photosensitive porphyrin dyes for dye-sensitized solar cells | NATIONAL CHUNG HSING UNIVERSITY (TW) | 2017-06-27 | — | — | US | disclosed |
| WO-2010122038-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2010-10-28 | — | — | WO | disclosed |
| WO-2009156284-A1 | NOVEL SUBSTITUTED PYRIDIN-2-ONES AND PYRIDAZIN-3-ONES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-12-30 | — | — | WO | disclosed |
| US-20090318448-A1 | 7-Dimethylamino-3-(2-methyl-3-{1-methyl-5-[5-(morpholine-4-carbonyl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro-pyridin-3-yl}-phenyl)-3H-quinazolin-4-one; asthma ; inhibit Btk | ROCHE PALO ALTO LLC | 2009-12-24 | — | — | US | disclosed |
| US-20090318448-A1 | 7-Dimethylamino-3-(2-methyl-3-{1-methyl-5-[5-(morpholine-4-carbonyl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro-pyridin-3-yl}-phenyl)-3H-quinazolin-4-one; asthma ; inhibit Btk | ROCHE PALO ALTO LLC | 2009-12-24 | — | — | US | disclosed |
| US-20090209536-A1 | AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2009-08-20 | — | — | US | disclosed |
| WO-2008157500-A1 | AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2008-12-24 | — | — | WO | disclosed |
| US-20080306076-A1 | MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH | SENOMYX, INC. (US) | 2008-12-11 | — | — | US | disclosed |
| US-20080234299-A1 | Quinazolinones | MERCK PATENT GMBH (DE) | 2008-09-25 | — | — | US | disclosed |
| EP-1885702-A2 | QUINAZOLINONES | Merck Patent GmbH (DE) | 2008-02-13 | — | — | EP | disclosed |
| WO-2006125555-A2 | QUINAZOLINONES | MERCK PATENT GMBH (DE) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306076-A1 | MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH | OR51E2, TAS2R50, TAS2R30 | NPC1 3785/4885MAPK1 3378/4885RAB9A 3534/4885 |
| US-20090209536-A1 | AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE | CNR2, CNR1, GPR18 | NPC1 1047/4885MAPK1 2435/4885RAB9A 640/4885 |
| US-20170362180-A1 | QUINOLONE COMPOUND | HAX1, NQO2, NHERF1 | NPC1 664/4885MAPK1 732/4885RAB9A 2337/4885 |
| US-20200055823-A1 | QUINOLONE COMPOUND | HAX1, NQO2, NHERF1 | NPC1 664/4885MAPK1 732/4885RAB9A 2337/4885 |
| US-20090318448-A1 | 7-Dimethylamino-3-(2-methyl-3-{1-methyl-5-[5-(morpholine-4-carbonyl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro-pyridin-3-yl}-phenyl)-3H-quinazolin-4-one; asthma ; inhibit Btk | BTK, LCK, SYK | NPC1 4499/4885MAPK1 361/4885RAB9A 1900/4885 |
| US-20080234299-A1 | Quinazolinones | H1-3, NDUFS3, CCNT1 | NPC1 2274/4885MAPK1 2202/4885RAB9A 229/4885 |
| US-10954252-B1 | Inhibitors of human immunodeficiency virus replication | EIF2AK2, REV1, POLR2E | NPC1 200/4885MAPK1 1570/4885RAB9A 1488/4885 |
| US-20190077762-A1 | QUINOLONE COMPOUND | HAX1, NQO2, NHERF1 | NPC1 764/4885MAPK1 724/4885RAB9A 2337/4885 |
| US-20210032207-A1 | QUINOLONE COMPOUND | HAX1, NQO2, CXCR1 | NPC1 691/4885MAPK1 735/4885RAB9A 2443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.